Analysts have grown much more cautious about Sionna Therapeutics Inc (NASDAQ: SION) after its closely watched cystic fibrosis programme stumbled, casting a long shadow over the biotech’s ambitions to challenge the market leader.
Shares in the Massachusetts-based company collapsed by around 91 per cent on Monday, tumbling from roughly US$50.00 to near US$4.50 after Sionna reported that its Phase 2a PreciSION CF trial of SION-719 had failed to meet its key activity endpoint. The company has abandoned plans to develop the drug as an add-on to standard care and now intends to take steps to preserve capital while it weighs its next moves.
Cystic fibrosis is a genetic condition caused by defects in the CFTR protein. These defects produce thick, sticky mucus that clogs the lungs and digestive system, leading to chronic infections, breathing difficulties and other serious complications.
Sionna created a drug called SION-719 to help stabilise and strengthen a key part of the faulty protein that causes cystic fibrosis. The goal was to make that protein work better than current treatments already do. In a small trial of 15 adults who have the most common form of the disease and were already taking Vertex Pharmaceuticals Inc‘s (NASDAQ: VRTX) (ETR: Vx1) main medicine (Trikafta), some patients got SION-719 on top of Trikafta while others got placebo. The drug only slightly lowered a key disease marker (sweat salt levels) by an average of 1 unit. That change was not meaningful and fell far short of the 10-unit improvement the company had hoped for.
The drug simply failed to show any real benefit beyond what Trikafta already delivers, and the small patient group produced highly variable sweat-test results that made it nearly impossible to detect a meaningful signal.
This clear miss removed a potential competitive threat to Vertex’s dominant cystic fibrosis franchise, which includes the blockbuster drug Trikafta. Vertex shares rose more than 6 per cent as investors concluded that the company’s competitive advantage remains robust and that near-term challenges to its products have diminished.
Analysts reacted swiftly to the plunge. BMO Capital Markets described the outcome as a “significant positive” for Vertex and evidence that its dominance is reaffirmed. Stifel Financial Corp (NYSE: SF) (FRA: 2SI) called the unequivocal failure surprising and disappointing, while Guggenheim and BTIG both cut their ratings to Neutral. Wedbush and Stifel also lowered price targets sharply, to US$5.00 and US$7.00.
Sionna closed the second quarter with US$268.3 million in cash, cash equivalents and marketable securities, which was enough, at the time, to fund operations into 2028. After the share price descent, the company’s market capitalisation fell below its cash balance. Management has said it will conserve resources while it continues to analyse the Phase 2a data and evaluate next steps for its earlier-stage SION-451 dual-combination programme, which showed acceptable outcomes in healthy volunteers.
The setback leaves Sionna’s future far less certain despite having a considerable cash reserve. Cash burn remains a major concern.
Sionna Therapeutics $SION plunges more than 90% today and BTIG downgrades it from Buy to Neutral 😂😂😂 Hilarious! pic.twitter.com/6go8w2puRI
— Barchart (@Barchart) August 10, 2026
Read more: Breath Diagnostics advances pre-op pneumonia screening with FDA breakthrough designation
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
